Colchicine Alternatives Compared
| Colchicine | Otezla (apremilast) | Adalimumab |
|
|---|
| Colchicine | Otezla (apremilast) | Adalimumab |
|
|||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Colchicine is effective for preventing gout flares in adults; however, colchicine may interact with several other medications and cause gastrointestinal side effects at higher dosages. Prescribed for... View more |
Prescription only
Otezla is a PDE4 inhibitor that may be used to treat adults with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet’s Disease. It may also be used to treat plaque psoriasis... View more |
Prescription only
Adalimumab is a TNF-alfa inhibitor that may be used to treat a wide range of different inflammatory conditions, such as rheumatoid Arthritis, psoriasis, ankylosing spondylitis, Crohn's disease, and... View more |
Related suggestions Behcet's Disease
|
|||||||||||||||||||||||
| More about Colchicine | More about Otezla (apremilast) | More about Adalimumab | ||||||||||||||||||||||||
| Ratings & Reviews | ||||||||||||||||||||||||||
|
Colchicine has an average rating of 7.3 out of 10 from a total of 102 ratings on Drugs.com. 64% of reviewers reported a positive effect, while 20% reported a negative effect. |
Otezla has an average rating of 5.2 out of 10 from a total of 440 ratings on Drugs.com. 35% of reviewers reported a positive effect, while 40% reported a negative effect. |
Adalimumab has an average rating of 6.4 out of 10 from a total of 737 ratings on Drugs.com. 55% of reviewers reported a positive effect, while 30% reported a negative effect. |
||||||||||||||||||||||||
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | ||||||||||||||||||||||||||
View all Colchicine side effects |
View all Otezla side effects |
View all Adalimumab side effects |
||||||||||||||||||||||||
| Drug Class | ||||||||||||||||||||||||||
| Generic Availability | ||||||||||||||||||||||||||
|
Lower cost generic |
Lower cost generic |
|||||||||||||||||||||||||
| Pricing and Coupons * Prices are without insurance | ||||||||||||||||||||||||||
View all Colchicine prices |
View all Otezla prices |
View all Adalimumab prices |
||||||||||||||||||||||||
| Dosage Forms | ||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||
| Brand Names | ||||||||||||||||||||||||||
| Colcigel Gel, Colcrys, Gloperba, Lodoco, Mitigare |
N/A |
Abrilada, Amjevita, Cyltezo, Hadlima, Hulio, Humira, Hyrimoz, Idacio, Simlandi, Yuflyma, Yusimry View more | ||||||||||||||||||||||||
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | ||||||||||||||||||||||||||
|
1.5 hours |
9 hours |
480 hours |
||||||||||||||||||||||||
| CSA Schedule 1 View glossary of CSA terms | ||||||||||||||||||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||||||||||
| Pregnancy Category | ||||||||||||||||||||||||||
|
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
Category B
No proven risk in humans
See the full pregnancy warnings document. |
||||||||||||||||||||||||
| Drug Interactions | ||||||||||||||||||||||||||
|
A total of 306 drugs are known to interact with Colchicine:
|
A total of 108 drugs are known to interact with Otezla:
|
A total of 550 drugs are known to interact with Adalimumab:
|
||||||||||||||||||||||||
| Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||||||||||||||||||
| Disease Interactions | ||||||||||||||||||||||||||
| First Approval Date | ||||||||||||||||||||||||||
|
July 29, 2009 |
March 21, 2014 |
N/A |
||||||||||||||||||||||||
| WADA Class View classifications | ||||||||||||||||||||||||||
|
N/A |
N/A |
N/A |
||||||||||||||||||||||||
| More Information | ||||||||||||||||||||||||||
| Patient Resources | ||||||||||||||||||||||||||
| Professional Resources | ||||||||||||||||||||||||||
| Related Treatment Guide | ||||||||||||||||||||||||||
|
||||||||||||||||||||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.